1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bayer AG

Bayer AG

BAY.WA
Bayer AGPL flagWarsaw Stock Exchange
220.00
PLN
+7.60
- -
216.13BMarket Cap
Bayer AG
BAY.WA
(Warsaw Stock Exchange)

Recent

price

220.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
42.43
44.17
48.06
48.56
49.99
55.73
41.97
39.56
39.06
44.36
42.14
44.87
51.65
48.49
47.44
46.39
46.19
Revenue per Share
1.57
2.99
2.91
3.86
4.14
4.97
5.44
8.29
1.8
4.17
-10.68
1.02
4.22
-2.99
-2.6
-3.68
-1.77
Basic EPS, GAAP
5.15
4.17
3.15
3.64
4.16
5.29
7.82
6.52
5.66
5.66
2.53
2.52
4.22
2.41
4.67
3.5
2.12
Free Cash Flow per Basic Share
1.4
1.5
1.65
1.9
2.1
2.26
2.55
2.67
2.56
2.66
2.82
2.03
2.02
2.42
0.13
0.13
0.13
Dividend per Share
22.41
22.86
21.96
24.66
23.93
28.88
36.1
43.79
49.21
48.1
31.07
33.61
39.47
33.52
32.48
26.41
30.11
Book Value per Share
-1.58
-0.29
-0.36
2.31
-12.96
-8.34
0.54
12.35
-31.56
-27.25
-31.88
-33.94
-25.51
-23.14
-20.58
-23.14
-20.13
Tangible Book Value per Share
827
827
827
827
827
827
833
885
941
982
982
982
982
982
982
982
982
Basic Weighted Avg Shares
35,088
36,528
39,741
40,157
41,339
46,085
34,943
35,015
36,742
43,545
41,400
44,081
50,739
47,637
46,606
45,575
45,375
Sales/Revenue/Turnover
7.78
11.62
13.2
12.68
13.59
14.74
17.22
17.45
-0.5
10.82
-1.72
15.67
14.45
16.87
7.14
13.47
17.98
Operating Margin (%)
3,556
2,769
2,988
2,896
2,920
3,332
3,063
2,660
6,241
5,367
13,259
3,056
6,503
10,020
8,783
2,785
3,751
Depreciation Expense
1,301
2,470
2,403
3,189
3,426
4,110
4,531
7,336
1,695
4,091
-10,495
1,000
4,150
-2,941
-2,552
-3,620
-1,738
Net Income, GAAP
23.88
26.49
22.76
24.27
24.26
23.36
21.31
29.04
26.3
15.53
- -
50.05
10.79
- -
- -
- -
36.09
Effective Tax Rate (%)
3.71
6.76
6.05
7.94
8.29
8.92
12.97
20.95
4.61
9.39
-25.35
2.27
8.18
-6.17
-5.48
-7.94
-3.83
Profit Margin (%)
7,483
6,678
5,906
5,005
6,724
6,841
11,910
16,480
7,820
9,224
-1,093
3,175
2,676
8,099
5,492
326
1,374
Working Capital
9,582
7,686
6,706
5,044
17,797
16,332
15,375
12,158
37,708
36,907
33,198
36,478
33,781
38,170
35,491
31,806
- -
LT Debt
18,896
19,271
18,551
20,804
20,218
25,445
31,897
36,861
46,064
47,433
30,675
33,168
38,926
33,078
32,045
26,063
29,708
Total Equity
6.8
10.35
13.98
13.78
12.44
12.18
9.81
8.53
-0.2
4.57
- -
4.67
8.47
- -
- -
- -
- -
Return on Invested Capital (%)
4.24
10.81
10.78
13.96
12.22
11.75
10.46
14.36
4.14
6.51
- -
2.28
7.57
- -
- -
- -
11.19
Return on Capital (%)
6.9
12.98
12.76
16.28
16.78
18.53
16.6
21.85
4.1
8.78
-26.99
3.15
11.56
-8.2
-7.87
-12.51
-5.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,647
- -
- -
LT Borrowings
30,779
- -
- -
LT Finance Leases
1,027
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
982
982
982
Market Capitalization
35,753
38,243
46,518

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
32,911
35,301
33,644
Cash, Cash Equivalents & STI
7,856
6,660
5,082
Accounts Receivable, Net
9,077
12,907
12,880
Inventories
12,335
12,014
11,971
Total Current Liabilities
32,585
33,460
32,270
Payables & Accruals
- -
- -
- -
ST Debt
4,647
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.26%
-18.67%
Free Cash Flow
7.19%
18.61%
-24.99%
Net Income, GAAP
-15.67%
12.64%
41.85%
Sales/Revenue/Turnover
0.57%
2.22%
-2.21%
Total Cash Common Dividend
-6.48%
-21.22%
-3.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,765
11,144
9,968
11,729
46,606
2025
13,738
10,739
9,660
11,438
45,575
2026
13,405
10,872
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.04
-0.03
-4.26
- -
-2.6
2025
1.32
-0.2
-0.98
- -
-3.68
2026
2.81
0.22
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.01
- -
0.13
2025
- -
0.11
0.01
- -
0.13
2026
- -
0.11
- -
- -
- -
Similar Companies
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
Pfizer Inc. (PFE.DE)
Eli Lilly and Company (LLY.DE)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
GSK plc (GS7.DE)
Otsuka Holdings Co., Ltd. (OTSKF)
Business
Bayer AG Bayer AG is a German multinational life sciences company that develops, manufactures and markets a broad range of pharmaceuticals, consumer health products and crop science solutions. The company operates through three main divisions: Pharmaceuticals, which focuses on prescription medicines in cardiology, women's health, oncology, hematology, ophthalmology and cell and gene therapy including key products such as Xarelto (rivaroxaban), Eylea (aflibercept), Kerendia, Nubeqa, Kogenate, Betaseron, Cipro (ciprofloxacin), Adempas (riociguat) and Xofigo (radium-223 dichloride); Consumer Health, offering over-the-counter medicines, nutritional supplements, medicated skincare and self-care solutions for pain and fever including Bayer Aspirin and Aleve, cardiovascular risk prevention, dermatology, digestive health, allergy, cough and cold, women's healthcare such as Yasmin and Yaz birth control pills; and Crop Science, providing crop protection products including herbicides like Roundup, Liberty (glufosinate), XtendiMax and Vynyty Citrus, fungicides such as Luna, Nativo, Xpro, Delaro Complete, Prosaro and Serenade, insecticides like Movento, Sivanto, Confidor, Belt and Velum/Verango, as well as high-value seeds, plant traits, digital farming solutions and environmental science products. Bayer AG conducts global operations across North America, Europe, Africa, Middle East, Asia-Pacific and Latin America, targeting healthcare providers, consumers, farmers and agricultural customers; the company was founded in 1863 and is headquartered in Leverkusen, Germany. Among its latest major developments, Bayer AG extended its multi-year strategic partnership with Ginkgo Bioworks in October 2025 to advance research on agricultural biologicals including microbial nitrogen fixation, complementing synthetic fertilizers; entered a collaboration worth up to $1.3 billion with Kumquat Biosciences in August 2025 for a KRAS G12D inhibitor cancer drug candidate targeting pancreatic, colorectal and lung cancers to bolster its precision oncology portfolio; added 1.2 billion euros ($1.37 billion) to Roundup litigation reserves in 2025 while raising sales guidance; implemented a Dynamic Shared Ownership operating model targeting 800 million euros in cost savings for 2025 as part of its turnaround strategy with improved performance expected from 2026; and continues heavy investment in R&D including cell and gene therapy units and ten planned blockbuster crop science products by 2029.